Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Trial ID # NCT03029598
Phase I/II
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-1
Drug Name Pembrolizumab
Alternate Drug Names MK3475, SCH 900475, Lambrolizumab, Keytruda
Drugs in Trial Carboplatin, Pembrolizumab
Eligible Participant

Platinum resistant ovarian cancer

Patients Enrolled

27; median 5 prior therapies (2-9)

Therapy Setting

Recurrence

Study Design

Open-Label, Non-randomized

Endpoints

ORR, DCR, PFS, OS, evaluated per RECIST

Biomarkers

Exploratory: PD-L1 status

Efficacy

ORR: 13% (3PR, n=23)
DCR: 78.2% (3PR, 15SD, n=23)
PFS: 4.6 months
OS: 12.83 months

7 of 23 evaluable patients (30.4%) had archival tumor with modified percent scoring ≥5 for PD-L1 and all achieved PR (3/7, 42.8%) or SD(4/7, 57.2%)

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE:

Conclusion

Promising activity of pembrolizumab with low dose carboplatin in heavily pretreated patients

Reference

Liao JB et al. Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer - interim results. ASCO (2019) 37 (suppl; abstr 5519)
http://abstracts.asco.org/239/AbstView_239_266891.html